Please select the option that best describes you:
Topics:
Melanoma/Skin Cancer • Medical Oncology
What is the current role of ctDNA in guiding the selection of adjuvant treatment for stage II-IIIA melanoma?
Would you omit treatment for stage IIIA melanoma with negative ctDNA, or add treatment for stage IIA with positive ctDNA?
Answer from: Medical Oncologist at Academic Institution
There are only retrospective, not prospective data on the Natera’s tumor-informed ctDNA platform (Signatera). I would be cautious in using the ctDNA result for clinical decision making. The gold standard is still the radiographic imaging - there is no test that will replace being able to see a m...
Sign in or Register to read more